The state is called latent tuberculosis infection, or LTBI. In LTBI, Mycobacterium tuberculosis bacteria are alive in the body but held in check by the immune system, so the person has no symptoms and cannot pass TB to others. The boundary matters: LTBI is not active TB disease, and it is not sterile cure either. Roughly 5–10% of people with LTBI will develop active TB disease over their lifetime, according to the World Health Organization, with most of that risk front-loaded into the first two years after infection.

What Latent Tuberculosis Infection Means in Plain English

Latent TB is a standoff, not a truce. The bacteria sit inside immune cells, chiefly macrophages, where they are walled off in structures called granulomas. They are not replicating enough to cause damage, and the immune system is not eliminating them. That balance is why the infection is described as "inactive germs" rather than "dead germs."

The word "latent" carries a specific clinical meaning: infected, asymptomatic, and non-infectious. An estimated one quarter of the world's population carries latent TB, per WHO's 2023 global estimates β€” about 2 billion people. That figure dwarfs the roughly 10.8 million people who developed active TB disease in 2023, the agency's most recent global count at the time of writing.

Three realistic pictures show how it presents. A nurse in Manila tests positive on an interferon-gamma release assay during a pre-employment screen, with a normal chest X-ray and no cough. A man in his thirties who grew up in a high-burden country is flagged by a contact-tracing program after a coworker develops TB. A child in a household with an infectious adult converts on a tuberculin skin test two months later.

What unites all three is the absence of disease: no fever, no night sweats, no weight loss, no cavities on imaging. The germ is present; the illness is not.

Why the Terminology Confuses People: Latent TB vs. Active TB Disease vs. TB Infection

The phrase "TB infection" gets used for two different things, which is where most confusion starts. In LTBI, the immune response is positive on a test but the person is well. In active TB disease, bacteria are multiplying, causing tissue damage, and usually producing symptoms. Same organism, different state.

A second false split trips people up: "exposed" is not the same as "infected." Exposure means contact with someone who had infectious TB. Infection means the bacteria got past the lungs' defenses and the immune system registered them β€” demonstrated by a positive IGRA or skin test, or by a documented conversion from negative to positive. Most exposed people never become infected.

Term Germ status Symptoms Infectious to others Standard test result
TB exposure Contact only, no established infection None No Negative tests, no conversion
Latent TB infection (LTBI) Live bacteria, contained None No Positive IGRA or skin test
Active TB disease Multiplying bacteria, tissue damage Cough, fever, sweats, weight loss Possible, depending on site Positive test plus abnormal imaging or lab proof
Post-TB lung disease Bacteria cleared, damage remains Variable No Negative cultures, residual scarring

The commonly confused term is "dormant." Dormant suggests the bacteria are asleep with no activity at all. In reality, latent TB bacteria show low-level metabolic activity and can wake up when immunity falters β€” which is why immunosuppressive drugs such as TNF inhibitors carry explicit TB screening warnings.

One misuse to retire: calling a positive skin test "having TB." A positive test proves sensitization, not disease. The U.S. Centers for Disease Control and Prevention estimates that without treatment, 5–10% of infected people will develop disease over their lifetime β€” and roughly half of that risk lands in the first two years. A positive test is a prompt for evaluation, not a diagnosis of illness.

How a Positive Test Separates Latent TB From Active TB

Testing for TB has two branches: proof of immune sensitization, and proof of disease. Latent TB lives entirely in the first branch. The tuberculin skin test (Mantoux) and interferon-gamma release assays (IGRAs such as QuantiFERON-TB Gold Plus and T-SPOT.TB) detect the immune system's memory of the bacterium. Neither can tell you whether live bacteria remain, which is a recognized limitation of both test types.

A positive IGRA or skin test combined with no symptoms and a normal chest X-ray points toward LTBI. A positive test plus an abnormal chest X-ray, a positive sputum smear or culture, or symptoms points toward active disease and triggers isolation and treatment. The chest X-ray is doing real work here: it rules out silent cavities that would change the diagnosis entirely.

Two edge cases matter. First, a negative test does not exclude infection in people whose immune systems are suppressed β€” advanced HIV, prolonged steroids, recent chemotherapy β€” because the test depends on a functioning immune response. Second, the skin test can be falsely positive after BCG vaccination, which is one reason IGRAs are preferred in BCG-vaccinated populations in many high-income settings.

If you are in the middle of this workup, the practical sequence is:

1: Complete the symptom review and chest imaging your clinician orders. 2: Get the IGRA or skin test result documented with the date. 3: Ask whether a sputum sample is needed to exclude active disease. 4: If active disease is excluded, ask specifically about LTBI treatment criteria.

Failure handling: if you are symptomatic β€” cough lasting more than two weeks, fever, night sweats, unexplained weight loss β€” do not wait for a routine LTBI appointment. Those symptoms change the pathway to active-disease evaluation, and delays carry transmission risk to household members.

What Wakes Latent TB Up: The Reactivation Triggers That Matter

Reactivation is the event that turns LTBI into active TB disease. It happens when the immune containment weakens. The best-documented triggers are HIV infection, especially with low CD4 counts; tumor necrosis factor inhibitors and other biologics; prolonged high-dose corticosteroids; organ transplantation; certain cancers and chemotherapy; poorly controlled diabetes; and severe undernutrition. WHO's global figures attribute a substantial share of incident TB to HIV coinfection and to these medical risk factors.

Tuberculosis is a notifiable disease in the United States and most countries, which is why a positive test gets reported even when the person feels fine. Public health departments use that report to offer contact tracing β€” finding the people who shared air with an infectious case β€” and to track LTBI treatment completion at the population level.

There is a risk figure worth keeping: a person with both LTBI and untreated HIV faces a far higher annual reactivation risk than someone with LTBI alone β€” the World Health Organization cites figures in the range of 5–15% per year for people living with HIV in the pre-antiretroviral era, versus the 5–10% lifetime figure in immunocompetent adults. That single comparison explains why TB preventive treatment is pushed hard in HIV clinics.

An illustrative arithmetic point: if you take a cohort of 1,000 people with LTBI and a lifetime reactivation risk of 10%, roughly 100 will develop active TB at some point without treatment. If half the risk concentrates in the first two years, about 50 cases appear in that window β€” a two-year rate of 5% β€” which is the number clinicians cite when they argue for prompt treatment rather than watchful waiting.

Why Treating Latent TB Is the Main Way to Break Transmission

Treating LTBI is prevention, and it is the closest thing public health has to interrupting TB's pipeline. WHO's End TB Strategy targets an 80% reduction in TB incidence by 2030 compared with 2015, and TB preventive treatment is a named pillar of that plan. The WHO Global Tuberculosis Report documents millions of people started on preventive treatment annually in recent years, with a large gap remaining among household contacts of confirmed cases.

The drugs are the same ones used in active disease, at shorter duration. Standard options include 3HP β€” isoniazid plus rifapentine once weekly for 12 weeks β€” 4R, which is daily rifampicin for four months, and 6H or 9H, which are daily isoniazid for six or nine months. The U.S. CDC's LTBI treatment guidance lists these regimens with the caveat that drug interactions and liver status determine the choice. A short-course regimen improves completion: a 12-dose course is easier to finish than 270 daily doses.

Prevention pays off in another way. Rifapentine-based regimens require attention to drug interactions, particularly with antiretrovirals and with warfarin-class anticoagulants, so the choice of regimen belongs to a clinician who knows your full medication list.

For anyone weighing treatment, the questions to bring to the appointment are concrete:

1: Which regimen fits my liver function, pregnancy status, and current medications? 2: What monitoring does the regimen require β€” baseline liver enzymes, symptom checks? 3: What is the local health department's role in my follow-up? 4: What symptoms should make me stop the drug and call immediately?

Stop-and-call symptoms include dark urine, yellowing eyes, right-upper-abdominal pain, and unexplained nausea β€” isoniazid and rifamycin regimens carry hepatotoxicity warnings, and prompt reporting is how serious injury gets caught early.

The 5–10% Number and Other Figures the Top Results Get Wrong

Most short summaries stop at "5–10% lifetime risk." The number is right, but the shape around it is usually missing, and the shape is what changes decisions. The U.S. CDC and WHO both describe a lifetime risk of 5–10% in people with intact immunity, with the majority of that risk concentrated in the first two years after infection.

WHO's global burden figures add context the top pages omit: roughly one quarter of the world's population is estimated to be infected with M. tuberculosis, and in 2023 the agency counted about 10.8 million new TB cases and 1.25 million deaths, a toll that keeps TB among the leading infectious killers. India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh, and the Democratic Republic of the Congo together account for the majority of cases, according to the same global report.

Region and setting change the numbers you should expect. A healthcare worker in a high-burden country faces repeated occupational exposure, and serial testing programs exist precisely because reinfection is possible β€” a point some patient-facing pages get wrong by implying one infection is the end of the matter. In low-burden countries, the positive predictive value of a test falls, which is why screening programs combine tests with risk questionnaires.

An original comparison worth building from these figures: if 1.25 million people died of TB in 2023 against roughly 10.8 million incident cases, the crude case fatality ratio works out to about 11.6% β€” and that is with treatment reaching most detected cases. Without treatment, historical and clinical sources put TB mortality far higher. The prevention argument sits directly on that arithmetic: shrinking the number of people who ever leave LTBI for active disease shrinks the pipeline feeding those deaths.

Who Should Get Screened for Latent Tuberculosis Infection

Screening is targeted, not universal in low-burden settings. The U.S. Preventive Services Task Force recommends latent TB screening in people at increased risk β€” those born in or who lived in high-burden countries, household contacts of known cases, residents and employees of congregate settings such as shelters and correctional facilities, healthcare workers, and people with immunosuppression. The task force's risk assessment tool lists country-of-origin and medical-risk factors explicitly.

Screening for LTBI is not the same as screening for active TB, and the order matters. Symptomatic people get active-disease evaluation first; only after disease is excluded does LTBI treatment apply. Getting this backward delays diagnosis and risks transmission.

Temporal edges are common in practice. Recent infection within two years is the highest-yield window for preventive treatment, and contact tracing programs prioritize it. A person infected in childhood in a high-burden country and never treated carries a different risk profile from a healthcare worker infected last year β€” both have LTBI, and their management conversations differ.

How Latent TB Treatment Works in Practice, With the Numbers

The practical decision is regimen choice and completion. The three standard families are weekly rifapentine-based short-course therapy, daily rifampicin monotherapy for four months, and daily isoniazid for six or nine months. All three reduce reactivation risk substantially; the differences are in completion rates, drug interactions, and monitoring burden.

Regimen Total doses Duration Common trade-off
3HP (isoniazid + rifapentine) 12 weekly doses 12 weeks Best completed; significant drug interactions
4R (rifampicin) Daily 4 months Drug interactions; green urine (harmless)
6H (isoniazid) Daily 6 months Long course; liver monitoring
9H (isoniazid) Daily 9 months Longest course; highest completion difficulty

The watch-for list is short and worth memorizing. Stop the regimen and contact your clinician for dark urine, jaundice, persistent nausea, or right-upper-quadrant pain, all of which flag possible drug-induced liver injury. Rash and fever also warrant a call. Alcohol use during treatment raises hepatotoxicity risk.

The biggest practical failure is not starting β€” it is stopping midway. The CDC has published data showing that 12-week weekly regimens achieve higher completion than nine months of daily self-administered isoniazid, which matters because an unfinished course gives partial protection at best. If a friend or relative is on LTBI treatment and feeling fine three weeks in, the honest advice is to finish the course anyway.

FAQ

What is a person's body storing after TB exposure called, in one phrase?

Latent tuberculosis infection, or LTBI β€” the state in which live M. tuberculosis bacteria are contained by the immune system without causing symptoms or transmitting infection. The one phrase that captures it clinically is "LTBI, confirmed by a positive IGRA or skin test with no evidence of active disease." Exposure alone is not LTBI; a positive test result is what moves you across the line.

Can latent TB turn active without warning?

Yes, sometimes, but not usually at random β€” reactivation clusters around identifiable immune events such as HIV progression, starting a TNF inhibitor, or prolonged steroids. A healthy person can still develop active disease from two years to decades after infection, which is why the 5–10% lifetime estimate is expressed across a lifetime, not per year. Fever, night sweats, weight loss, or a cough over two weeks warrant immediate evaluation.

Can a person with latent TB pass it to family members?

No, LTBI is not infectious. Transmission requires active TB β€” most often pulmonary disease with bacteria reaching the air through coughing or singing. The protective logic of contact tracing runs the other way: an infectious active case is the one that spreads, which is why public health teams test household contacts, including young children, who face a higher risk of rapid progression.

Is latent TB generally curable with treatment?

Treatment substantially reduces the risk of progression rather than guaranteeing permanent protection. Preventive regimens cut reactivation risk by roughly 60–90% depending on the regimen and adherence, and no large-scale study has claimed zero risk afterward. This is why a treated person with new exposure should still be risk-assessed; the value of treatment is risk reduction, not a forever guarantee.

Does a positive TB test always mean latent TB?

No β€” a positive test plus symptoms or an abnormal chest X-ray points to active TB disease, not latent infection, and the pathway changes to isolation, sputum testing, and full multidrug treatment. A positive test with a normal X-ray and no symptoms fits LTBI. A negative test in an immunosuppressed person also fails to rule out infection, so the test result alone decides nothing.

Why does latent TB risk depend on where a person lives?

Because infection prevalence and reinfection pressure vary enormously by setting. WHO's global estimates place about a quarter of the world's population in the infected category, concentrated in countries such as India, Indonesia, China, the Philippines, Pakistan, and Nigeria. A healthcare worker in a high-burden setting faces repeated exposure that a worker in a low-burden country does not.

Does breast milk transmit latent TB?

No. TB bacteria do not pass through breast milk, and latent TB is not transmitted at all. A mother with untreated active pulmonary TB can transmit by droplet, which is why a mother with a cough is assessed rather than excluded from feeding. Regimen choice and neonate preventive treatment, where indicated, are clinician decisions.

What is the cost of not treating latent TB?

Answering that question depends on local price structures β€” treatment for active TB is longer, more expensive, and carries higher individual and public health costs than preventive therapy. The WHO End TB Strategy's 80% incidence-reduction target by 2030 is built on diagnosing and treating active cases while treating latent infection in high-risk groups; the calculation is about somebody's family budget, and it affects no one's tax bill.

This article is general educational information about tuberculosis states and their clinical terminology. It is not a diagnosis, a treatment plan, or a substitute for individualized medical advice. Tuberculosis screening, preventive treatment decisions, and medication choices depend on your medical history, medications, immune status, and local guidelines, so consult a licensed clinician and your local health department before acting on anything here. If you have a cough with fever, night sweats, or weight loss, seek prompt evaluation; if you are in danger or in a mental health crisis, contact local emergency or crisis services.